Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.79 |
| ▸ | HSPA8 | P11142 | 5/20 | 0.66 |
| ▸ | CDK1 | P06493 | 2/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.61 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.61 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.55 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | ADK | P55263 | 4/20 | 0.50 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780006 | 0.88 | HIF1A (1.00) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL2384313 | 0.88 | HIF1A (1.00) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL20141370 | 0.88 | HIF1A (0.81) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL22111064 | 0.88 | HIF1A (0.81) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL12284814 | 0.88 | HIF1A (1.00) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL2384317 | 0.88 | HIF1A (1.00) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL22111053 | 0.85 | HIF1A (0.77) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL20141988 | 0.85 | HIF1A (0.77) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL30131081 | 0.85 | HIF1A (0.77) | HIF1AHSPA8CDK1CDK2CCNB1 | |
| SCHEMBL20141359 | 0.84 | HIF1A (0.75) | HIF1AHSPA8CDK1CDK2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11617753-B2 | Methods of treating and inhibiting Ebola virus infection | OYAGEN, INC. (US) | 2023-04-04 | — | — | US | claimed |
| US-20200188404-A1 | METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2020-06-18 | — | — | US | claimed |
| EP-3538108-A1 | METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION | Oyagen, Inc. (US) | 2019-09-18 | — | — | EP | claimed |
| WO-2018089306-A1 | METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION | OYAGEN, INC. (US) | 2018-05-17 | — | — | WO | claimed |
| US-11779585-B2 | Method for treating coronavirus infections | OYAGEN, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230285434-A1 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | OYAGEN, INC. | 2023-09-14 | — | — | US | disclosed |
| US-11738025-B2 | Method for treating coronavirus infections | OYAGEN, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233591-A1 | METHOD FOR TREATING POXVIRIDAE INFECTIONS | OYAGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11617753-B2 | Methods of treating and inhibiting Ebola virus infection | OYAGEN, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-4100019-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | Oyagen Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220378815-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | OYAGEN, INC. (US) | 2022-12-01 | — | — | US | disclosed |
| WO-2021211759-A1 | METHOD FOR TREATING POXVIRIDAE INFECTIONS | OYAGEN, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021158701-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | OYAGEN, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158248-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | OYAGEN, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210236497-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | OYAGEN, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-20200188404-A1 | METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES | 2020-06-18 | — | — | US | disclosed |
| EP-3538108-A1 | METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION | Oyagen, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089306-A1 | METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION | OYAGEN, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11617753-B2 | Methods of treating and inhibiting Ebola virus infection | EIF2AK2, MAVS, BST2 | HIF1A 337/4885HSPA8 560/4885CDK1 4213/4885 |
| US-20230285434-A1 | METHOD FOR TREATING ARENAVIRIDAE INFECTIONS | MPO, LIPA, CAT | HIF1A 2536/4885HSPA8 306/4885CDK1 4494/4885 |
| US-11779585-B2 | Method for treating coronavirus infections | ACE2, ACE, SARS1 | HIF1A 3141/4885HSPA8 4424/4885CDK1 3778/4885 |
| US-20220378815-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | HIF1A 3141/4885HSPA8 4424/4885CDK1 3778/4885 |
| US-20210236497-A1 | METHOD FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | HIF1A 3054/4885HSPA8 4394/4885CDK1 3907/4885 |
| US-20200188404-A1 | METHODS OF TREATING AND INHIBITING EBOLA VIRUS INFECTION | EIF2AK2, MAVS, BST2 | HIF1A 337/4885HSPA8 560/4885CDK1 4213/4885 |
| US-11738025-B2 | Method for treating coronavirus infections | ACE2, ACE, SARS1 | HIF1A 3054/4885HSPA8 4394/4885CDK1 3907/4885 |
| US-20230233591-A1 | METHOD FOR TREATING POXVIRIDAE INFECTIONS | ITPA, VAC14, MAVS | HIF1A 3831/4885HSPA8 1528/4885CDK1 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.